Redeye returns with a more optimistic outlook following Polygiene’s Q3 2025 report, which presented mixed figures but confirmed our expectations of a recovery in Q4 ’25. We make smaller positive estimate adjustments while our valuation range remains intact. We argue that the macro effects are transitory, staying positive to the long-term case which trades at an attractive valuation.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/